FIRST AMENDMENT TO OFFER LETTEROffer Letter • March 26th, 2020 • Equillium, Inc. • Pharmaceutical preparations • California
This First Amendment to Offer Letter (this “Amendment”), amending that certain Offer Letter (the “Offer Letter”), dated August 1, 2018, by and between Equillium, Inc. (the “Company”) and Krishna Polu, M.D. (the “Executive”), is entered into effective as of January 1, 2020. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Offer Letter.
SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 26th, 2020 • Equillium, Inc. • Pharmaceutical preparations
This Second Amendment To Collaboration and License Agreement (“Amendment”) is made and entered into effective as of April 22, 2019 (the “Amendment Date”), by and between Equillium, Inc., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla, California 92037, USA (“Equillium”), and Blocon Limited, a company incorporated and existing under the laws of India and having its registered office at 20th KM, Hosur Road, Electronics City P.O. Bangalore 560 100, India (“Biocon”).
FIRST AMENDMENT TO OFFER LETTEROffer Letter • March 26th, 2020 • Equillium, Inc. • Pharmaceutical preparations • California
This First Amendment to Offer Letter (this “Amendment”), amending that certain Offer Letter (the “Offer Letter”), dated June 1, 2018, by and between Equillium, Inc. (the “Company”) and Bruce D. Steel (the “Executive”), is entered into effective as of January 1, 2020. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Offer Letter.
FIRST AMENDMENT TO OFFER LETTEROffer Letter • March 26th, 2020 • Equillium, Inc. • Pharmaceutical preparations • California
This First Amendment to Offer Letter (this “Amendment”), amending that certain Offer Letter (the “Offer Letter”), dated January 19, 2018, by and between Equillium, Inc. (the “Company”) and Christine Zedelmayer (the “Executive”), is entered into effective as of January 1, 2020. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Offer Letter.
FIRST AMENDMENT TO OFFER LETTEROffer Letter • March 26th, 2020 • Equillium, Inc. • Pharmaceutical preparations • California
This First Amendment to Offer Letter (this “Amendment”), amending that certain Offer Letter (the “Offer Letter”), dated June 1, 2018, by and between Equillium, Inc. (the “Company”) and Daniel M. Bradbury (the “Executive”), is entered into effective as of January 1, 2020. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Offer Letter.
THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 26th, 2020 • Equillium, Inc. • Pharmaceutical preparations
This Third Amendment to Collaboration and License Agreement (“Amendment”) is made and entered into effective as of December 10, 2019 (the “Amendment Date”), by and between Equillium, Inc., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla, California 92037, USA (“Equillium”), and Biocon Limited, a company incorporated and existing under the laws of India and having its registered office at 20th KM, Hosur Road, Electronics City P.O. Bangalore 560 100, India (“Biocon”).
